Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis
Frontiers in Pharmacology · 29.09.2025 · 16
DOI: 10.3389/fphar.2025.1627714 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.09.2025. Verfasst von Ye Min und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is still controversy in the medical community about whether asymptomatic hyperuricemia (AH) requires drug treatment. Herbal medicines (HM) are considered a potential intervention for the treatment of hyperuricemia.
Objectives
This study aimed to investigate the efficacy and safety of HM for asymptomatic HUA. Materials and Methods A Bayesian network meta-analysis was conducted for patients with asymptomatic HUA in randomized controlled trials identified in PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang database, China Biomedical Database (CBM), and China Science and Technology Journal Database (VIP) were searched from their inception to 1 Jan 2025. Outcomes included the serum uric acid (SUA), secondary outcomes (TC, TG, HDL or HDL-C, LDL or LDL-C, and traditional Chinese medicine symptom scores), and adverse events. This study was registered in PROSPERO (CRD42024459357).
Results
All evaluated HM formulations except Lily Plantago Seed tea demonstrated significant SUA reduction versus non drug therapy (NDT), achieving effect sizes spanning from -197.48 (95% CI −249.88 to −145.56) to −14.6 (95% CI −62.09 to 33.31). Probabilistic ranking identified Xuezhikang capsule as the most effective agent for SUA reduction (98.7%), with concurrent improvements in lipid profiles including TC, TG, and HDL levels. Therapeutic benefits extended to TCM symptom scores across all interventions (OR range 3.15–28.44), suggesting broader treatment potential for HUA management. No serious adverse events were documented throughout the trials.
Conclusion
HM interventions demonstrate potential efficacy in managing AH, showing significant reductions in SUA levels alongside beneficial effects on lipid profile modulation and TCM symptom alleviation. While these findings suggest therapeutic promise, the preliminary nature of the evidence necessitates rigorous validation through methodologically robust clinical trials. Systematic Review Registration identifier CRD42024459357.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
- Guangdong Yifang Pharmaceutical Co., Ltd., Foshan, China.
- Graduate College, Beijing University of Chinese Medicine, Beijing, China.
- Chengdu University of Chinese Medicine, Chengdu, Sichuan, China.
- Institute of Metabolic Diseases, Guang' anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zitieren
APA
Min, Y., Xiao, F., Zhou, L., Fan, M., Luo, J., & Zhao, L. (2025). Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1627714
Vancouver
Min Y, Xiao F, Zhou L, Fan M, Luo J, Zhao L. Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1627714
BibTeX
@article{Min2025,
author = {Min, Ye and Xiao, Fengqin and Zhou, Ling and Fan, Meng and Luo, Jinli and Zhao, Linhua},
title = {Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1627714}
}
EUVIMED